Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has shared an update.
Hemogenyx Pharmaceuticals announced the successful treatment of a second patient in their Phase I clinical trial of HG-CT-1, a CAR-T therapy for relapsed/refractory acute myeloid leukemia. The treatment met initial safety criteria and showed early signs of efficacy, marking a significant step in addressing a critical unmet need in leukemia treatment. The trial aims to evaluate safety, efficacy, and overall survival, with further updates to follow as the trial progresses.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical-stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 40,194
Technical Sentiment Signal: Sell
Current Market Cap: £7.66M
Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue